Significant changes at Johnson & Johnson were among the most-read medtech news stories on MassDevice over the past year.
However, a major lawsuit over an ERP software project garnered the most attention.
Here’s a countdown of the medtech news bringing in the most pageviews on MassDevice over the past year:
10. Dexcom is getting a new CEO
Over Sayer’s 10 years as Dexcom’s CEO, he led the company to significant growth. Dexcom’s market capitalization grew roughly $20 billion, to more than $26 billion, during his tenure.
The surgical robotics space also saw a longtime CEO step down. Go to Medical Design & Outsourcing for a full roundup of corporate leadership changes that made medtech news this year.
Purchase and download our Medtech Market Intelligence Report about the CGM market.
9. Investor syndicate acquires HistoSonics for $2.25B
HistoSonics’ Edison platform uses focused ultrasound energy — delivered via a robotic arm — to provide histotripsy for the noninvasive destruction of tumors. Edison mechanically destroys and liquifies targeted tissue and tumors without the invasiveness or toxicity of traditional procedures.
8. Boston Scientific discontinues Acurate TAVR sales
In May, Boston Scientific said it would halt global sales of its Acurate neo2 and Acurate Prime transcatheter aortic valve replacement (TAVR) systems, citing an increased regulatory burden in the U.S. and Europe. The Accurate TAVR systems had been Boston Scientific’s next bet to compete against Edwards Lifesciences and Medtronic in the space after the discontinuation of its Lotus TAVR program five years ago..
Despite the TAVR setback, analysts say Boston Scientific is set for continued durable growth on the strength of medtech including its Farapulse pulsed field ablation, Watchman FLX left atrial appendage closure (LAAC) device, and more.
7. Bob White takes over at Olympus
White told MassDevice earlier this year: “I believe in small wins that create momentum and drive the ability to change, but understand it’s building on the things that made Olympus great anyway.”
Purchase and download our Medtech Market Intelligence Report about the surgical robotics market.
6. Medtronic executive changes
White left Medtronic in early 2024. The medtech giant has seen numerous leadership changes in recent years as it reorganizes, and more changes could be on the way as the company works with activist investor Elliott Investment Management.
Medical Design & Outsourcing has a full rundown of the leadership changes that Medtronic saw this year.
5. Medtech continues to see some layoffs
The medical device industry also had more layoff news this year as companies continue to refocus. For example, the restrategizing at Olympus under White includes a net reduction of roughly 2,000 positions across its global workforce — about 7% of the 29,297 headcount it disclosed on March 31.
Historically, medtech has coped better than other industries with economic uncertainty, but it’s still facing challenges ranging from tariffs to turmoil at the FDA.
Some layoffs at Cardinal Health and Intuitive also drew attention from MassDevice’s audience this year.
4. Stryker sells its spine business
The spine-treating tech space continues to see major changes. Stryker announced this year that it was selling its spinal implants business to Viscogliosi Brothers, creating a new company called VB Spine. Zimmer Biomet spun off its spine implants business in 2022; it’s now the privately held Highridge Medical.
3. Boston Scientific’s new Twin Cities facility
2. Significant changes at J&J
This year proved transformative for Johnson & Johnson MedTech, the world’s second-largest medtech company, which is seeing strong Cardiovascular business growth driven by major acquisitions in recent years. Those deals include the $13.1 billion purchase in 2024 of Shockwave Medical and its intravascular lithotripsy (IVL) technology that uses sonic waves to treat calcified arterial plaque.
To focus the company even more, J&J announced in October that it intends to separate its DePuy Synthes Orthopaedics business. Johnson & Johnson MedTech also plans to soon enact an organizational restructuring, changing the way its business units operate.
Tim Schmid, J&J EVP and global medtech chair, shared the company’s growth playbook during our DeviceTalks West event in Santa Clara, California, in October.
Download our free Cardio Device Companies Special Report.
1. Zimmer Biomet sues Deloitte for $172M over ‘disaster’ of a project
In early September, Zimmer Biomet sued Deloitte in the Supreme Court of the State of New York in Manhattan, claiming in a lawsuit that the British accounting and consulting firm falsely sold the ortho device giant on an enterprise resource planning (ERP) software system that ended up costing tens of millions of dollars to fix.
“While litigation is never our first choice, Deloitte strung us along with repeated false assurances, both before the contract and before the system go-live,” Zimmer Biomet General Counsel Chad Phipps told MassDevice in an emailed statement. “This is not the conduct we expect nor tolerate from our business partners, and we intend to hold Deloitte accountable for its actions, which not only seriously disrupted our business, but also put patient care at risk.”
Deloitte is fighting the suit, saying that ZB’s complaint reads like a “through the looking glass’” version of its relationship with Deloitte.
And here’s our final DeviceTalks Weekly podcast episode of 2025, featuring our entire medtech editorial staff discussing the year’s top events:
